Kennedy Capital Management, Inc. Eagle Pharmaceuticals, Inc. Transaction History

Kennedy Capital Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.26 - $6.51 $76,939 - $117,577	-18,061 Reduced 24.47%	55,748 $292,000
Q4 2023 Feb 14, 2024	BUY	$4.63 - $15.21 $172,805 - $567,682	37,323 Added 102.29%	73,809 $386,000
Q3 2023 Nov 14, 2023	BUY	$15.21 - $22.88 $554,952 - $834,799	36,486 New	36,486 $575,000
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $4.41 Million - $5.47 Million	-96,191 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$43.79 - $55.78 $197,624 - $251,735	-4,513 Reduced 4.48%	96,191 $5.37 Million
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $459,865 - $555,182	-12,476 Reduced 11.02%	100,704 $4.31 Million
Q1 2021 May 14, 2021	BUY	$40.32 - $50.97 $4.56 Million - $5.77 Million	113,180 New	113,180 $4.72 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.